Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Chemo(Radio)Therapy in Esophageal Cancer
NCT02735239Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Jun 2016
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in esophageal cancer, sponsored by Ludwig Cancer Research. Started Jun 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02735239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735239.